Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment
Schlieren, Switzerland – April 14, 2026 New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model InSphero AG, the global leader in 3D cell-based assays and organ-on-chip systems, today announced the commercial launch of the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput screening solution for early...
Biognosys Group Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson’s Disease Research Through the Development of Improved Biomarker Assays
Collaboration supports global LRRK2 Investigative Therapeutics Exchange (LITE) to accelerate development of reliable biomarkers for Parkinson’s disease April 14, 2026 – ZURICH, Switzerland. Biognosys Group, a leading provider of proteomics, metabolomics, and lipidomics solutions, today announced a major collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the...